“100% Tariff Shock!” Trump Targets Imported Drugs, India in Focus

In a bold and controversial move, the administration of Donald Trump has announced tariffs of up to 100% on certain imported patented drugs, aiming to force pharmaceutical companies to shift manufacturing back to the United States.

The decision is expected to have a major impact on global drug supply chains, especially for countries like India that are key exporters of medicines to the US.

What Does the New Tariff Policy Say?

The newly announced tariffs will apply primarily to patented drugs imported from countries that do not have tariff agreements with the US or from companies that fail to meet pricing conditions set by Washington.

According to officials, the move is designed to reduce America’s dependence on foreign-made essential medicines and strengthen domestic production capabilities.

Which Drugs Will Be Affected?

The policy clearly targets patented medicines, with tariffs going as high as 100% in some cases.

However, there is a significant relief for consumers and exporters—generic drugs are currently exempt from these tariffs, ensuring that low-cost medicines remain accessible.

Why Is India a Key Target?

India, known as the “pharmacy of the world,” exports a large volume of medicines to the US.

Under the new rule, patented drugs manufactured in India by companies that fail to submit US-based production plans could face the full 100% tariff, making exports significantly more expensive.

What Are “Reshoring Plans”?

The US government has given pharmaceutical companies a deadline to shift operations:

Large companies have 120 days to submit plans to move manufacturing to the US
Smaller firms have 180 days before the tariffs come into force

Failure to comply could result in heavy financial penalties under the new tariff regime.

Which Countries Got Exemptions?

Not all countries are being treated equally under the new policy.

The US has granted partial or full exemptions to key allies:

European Union, Japan, South Korea, and Switzerland will face a reduced 15% tariff
Britain has secured zero tariffs on medicines for three years under a special agreement

These exemptions highlight the strategic trade partnerships influencing US policy decisions.

Is This Linked to Trump’s Earlier Trade War?

Yes, the move is seen as an extension of Trump’s aggressive trade policies.

It comes nearly a year after his “Liberation Day” tariffs, which disrupted global trade before being struck down by the Supreme Court of the United States.

Despite that setback, the administration is continuing similar strategies through alternative legal routes.

What Questions Are Being Raised?

Will Drug Prices Increase in the US?

Experts fear that higher import tariffs on patented drugs could lead to increased costs for American patients.

Can Pharma Companies Shift Manufacturing So Quickly?

The short deadlines of 120–180 days may pose serious challenges for global pharmaceutical firms.

Will India Lose Its Export Advantage?

India’s pharma sector could face pressure, especially in patented drug segments.

Is This a New Trade War Trigger?

The selective exemptions and aggressive tariffs may strain relations with countries left out of the deal.

What’s the Bigger Economic Impact?

Alongside drug tariffs, Trump has also announced fresh duties on steel, aluminium, and copper, citing national security concerns.

This signals a broader push toward economic nationalism, with the US aiming to reduce dependence on imports across critical sectors.

What Happens Next?

Pharmaceutical companies worldwide are now racing against time to respond.

Whether they shift manufacturing to the US or absorb the tariff costs will determine the future of global drug pricing and supply chains.